🧬 biology

A mathematical model of lung cancer incorporating drug resistance, macrophage polarization, and immune escape

This study develops and validates a data-driven, non-linear ODE model to quantify the complex dynamics of drug resistance, macrophage polarization, and immune escape in lung cancer, deriving the basic reproduction number ( $R_0$ ) and identifying key therapeutic parameters through sensitivity analysis and rigorous model selection.

Original authors: Willie Kudakwashe Chidaushe, Thomas Musora, Steady Mushayabasa

Published 2026-09-11

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Willie Kudakwashe Chidaushe, Thomas Musora, Steady Mushayabasa

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Lung cancer remains one of the most formidable challenges in modern medicine, not just because the disease is aggressive, but because it is a master of adaptation. Inside a patient's body, a tumor is not a single, static mass of cells; it is a shifting ecosystem where different types of cells compete, cooperate, and evolve. Among the most critical players in this hidden world are immune cells called macrophages. In a healthy body, these cells act as guardians, identifying and destroying invaders. However, cancer cells are cunning; they can trick these guardians, forcing them to switch from a protective role to one that actually helps the tumor grow and hide from treatment. This process, known as macrophage polarization, creates a shield around the cancer, making it harder for drugs to work and allowing the disease to develop resistance. Understanding how these microscopic negotiations happen is essential for designing treatments that do not just kill cancer cells temporarily, but prevent them from evolving into untreatable forms.

Researchers at Chinhoyi University of Technology and the University of Zimbabwe have built a detailed mathematical map to explore these complex interactions. Rather than working with physical patients or petri dishes, they constructed a virtual laboratory using a system of equations to simulate the behavior of lung cancer over time. This digital model tracks several key groups: cancer cells that are sensitive to drugs, cancer cells that have become resistant, immune cells that attack the tumor, and the two distinct types of macrophages—one that fights cancer and one that helps it. The researchers also included the flow of chemotherapy drugs into the system, calculating how the medication moves through the body and interacts with these cellular populations. By running this simulation, they could observe how the tumor evolves under different conditions, watching how the balance shifts between immune defense and cancer survival.

The simulation revealed a clear pattern of how the disease progresses when left to its own devices versus when treated. When chemotherapy is introduced, the population of drug-sensitive cancer cells drops rapidly, as the medication and the immune system work together to eliminate them. However, the model showed that this initial success can be a double-edged sword. As the sensitive cells die, the pressure they face causes a small fraction of them to mutate into resistant forms. These resistant cells, which are less affected by the drug, begin to grow. In the early stages of the simulation, the resistant population rises, creating a new threat. Yet, the model also showed that the immune system, specifically the macrophages that fight cancer, can eventually regain control. If the immune response remains strong, it can suppress even the resistant cells, driving their numbers down over a period of about 300 days. This suggests that the key to long-term success lies not just in killing the cancer, but in maintaining a robust immune environment that keeps the resistant cells in check.

A central finding of the study is the critical role of macrophage behavior. The researchers found that when macrophages are tricked into their "helpful" state, they actively promote tumor growth and shield the cancer from immune attacks. Conversely, when these cells are encouraged to stay in their "fighting" state, they significantly reduce the tumor's ability to survive. The model demonstrated that the most effective strategy is not simply to pour more chemotherapy into the system, but to combine drug treatment with therapies that force the macrophages to switch back to their protective role. This dual approach prevents the cancer from finding a safe haven and stops the resistant cells from taking over. The researchers used a mathematical tool called the basic reproduction number to determine a threshold for tumor survival. They found that if the conditions inside the tumor allow the cancer to reproduce faster than the immune system and drugs can eliminate it, the disease will persist. However, if treatments can push this number below a critical point, the tumor will eventually shrink and disappear.

The study also addressed the practical question of how to dose chemotherapy. The researchers tested different schedules to see how the amount of drug and the timing of its delivery affected the outcome. They discovered that while high doses of chemotherapy can quickly reduce the tumor size, they also increase the risk of selecting for resistant cells if the immune system is not strong enough to finish the job. The model suggests that the best approach is a carefully balanced regimen that maintains a steady level of drug in the body while simultaneously supporting the immune system. This prevents the cancer from adapting to the treatment and ensures that the immune cells remain active enough to clear out any remaining resistant cells. The researchers confirmed that their simplified model, which treats drug concentration as a steady level rather than a constantly changing variable, was just as accurate as a more complex version. This finding is significant because it means doctors and researchers can use simpler, faster models to design treatment plans without losing accuracy.

Ultimately, this work provides a blueprint for understanding why some lung cancer treatments fail and how to prevent it. The simulation shows that the battle against cancer is not a single event but a continuous struggle between the tumor's ability to adapt and the body's ability to respond. By mapping out the specific ways in which drug resistance emerges and how immune cells can be influenced, the researchers have identified clear targets for new therapies. The results suggest that future treatments should focus on a combination of strategies: using drugs to kill the cancer, while simultaneously using other agents to reprogram the immune system's helpers to stay on the side of the patient. This approach offers a path toward turning a disease that often becomes resistant and fatal into one that can be managed and potentially eradicated, offering hope for more effective and personalized care for those facing lung cancer.

Technical Summary: A Mathematical Model of Lung Cancer Incorporating Drug Resistance, Macrophage Polarization, and Immune Escape

Problem Statement
Lung cancer remains a leading cause of global mortality, with treatment failure frequently driven by the emergence of drug-resistant sub-populations and complex interactions within the tumor microenvironment (TME). A critical challenge lies in understanding the dynamic cross-talk between malignant cells, drug-resistant strains, and immune components, specifically the polarization of macrophages. While M1 macrophages typically exhibit anti-tumor activity, the tumor microenvironment often reprograms them into M2 phenotypes, which are immunosuppressive and promote tumor growth and drug resistance. Furthermore, immune escape mechanisms allow tumors to evade detection, complicating the efficacy of both chemotherapy and immunotherapy. Current models often lack a unified framework that simultaneously quantifies the evolutionary dynamics of drug resistance, the phenotypic switching of macrophages (M1/M2), and the resulting immune escape.

Methodology
The authors formulate a data-driven, non-linear system of ordinary differential equations (ODEs) to model the temporal evolution of lung cancer. The model is a six-dimensional compartmental system comprising:

Drug-sensitive tumor cells ( $T_S$ ) and drug-resistant tumor cells ( $T_R$ ).
Cytotoxic CD8+ T cells ( $E$ ).
M1 macrophages (anti-tumor) and M2 macrophages (pro-tumor/immunosuppressive).
Chemotherapy concentration ( $C$ ).

The model incorporates several biophysical and biological mechanisms:

Logistic Growth: Tumor cells grow logistically with a carrying capacity ( $K_T$ ), competing for resources.
Macrophage Polarization: M1 and M2 populations undergo density-dependent proliferation and phenotypic switching. M2 macrophages promote tumor growth and induce resistance, while activated T cells can repolarize M2 cells back to the M1 phenotype.
Drug Resistance Dynamics: Resistance arises via spontaneous mutation, M2-mediated induction, and chemotherapy-induced selective pressure. A function $\mu(M_2, C)$ quantifies the rate at which sensitive cells acquire resistance.
Pharmacokinetics: Chemotherapy is modeled using a one-compartment pharmacokinetic approach with constant infusion and first-order elimination.
Immune Interactions: Cytotoxic T cells and M1 macrophages eliminate tumor cells, while M2 macrophages suppress T-cell activity.

Mathematical Analysis
The study rigorously validates the model's well-posedness, proving that solutions remain non-negative and uniformly bounded within a compact invariant region.

Steady States and Stability: The authors derive the disease-free equilibrium and analyze its local stability. They establish conditions for the existence of a unique positive endemic equilibrium.
Basic Reproduction Number ( $R_0$ ): Using the next-generation matrix operator, the authors analytically derive $R_0$ . This threshold determines whether the tumor population will persist ( $R_0 > 1$ ) or decline ( $R_0 < 1$ ).
Global Stability: A Lyapunov function is constructed to prove the global asymptotic stability of the endemic equilibrium under specific parameter constraints, utilizing LaSalle's Invariance Principle.
Optimal Control: The study formulates an optimal control problem using Pontryagin's Minimum Principle (PMP). The control variable $u(t)$ represents the time-dependent chemotherapy infusion rate. The objective functional minimizes the total tumor burden ( $T_S + T_R$ ) and the cost of drug administration (toxicity), subject to physiological constraints.
Model Selection: The authors compare the full six-dimensional model against a reduced five-dimensional model (where drug concentration is treated as a quasi-steady-state constant) using Akaike Information Criterion (AIC), small-sample corrected AIC (AICc), and Bayesian Information Criterion (BIC).

Key Results

System Dynamics: Numerical simulations demonstrate that under baseline parameters, chemotherapy combined with immune surveillance can drive sensitive tumor cells toward extinction. Resistant cells initially proliferate due to mutation and reduced drug sensitivity but are eventually controlled by the sustained immune response (specifically M1 macrophages and T cells), provided the immune system is not fully exhausted.
Sensitivity Analysis:
- Local Sensitivity: Identifies the neoplastic proliferation rate, macrophage phenotypic transition rates, and therapeutic efficacy parameters as primary drivers of $R_0$ and tumor burden.
- Global Sensitivity: Utilizing Latin Hypercube Sampling (LHS) and Sobol indices, the study confirms that parameters related to M2-mediated resistance induction and T-cell recruitment significantly influence model outputs.
Optimal Control Profiles: The optimal control strategy suggests adaptive dosing schedules. The analysis reveals a trade-off: lower control costs ( $w_3$ ) allow for aggressive, near-maximal dosing to suppress tumors rapidly, while higher costs necessitate conservative schedules to minimize toxicity. The optimal infusion rate is shown to be a function of the adjoint variable associated with drug concentration.
Model Comparison: Information criteria (AIC, AICc, BIC) consistently favor the reduced model over the full model. This indicates that simplifying the drug concentration dynamics to a quasi-steady-state does not significantly reduce explanatory power, offering a more parsimonious and statistically sound description of the system.

Significance and Claims
The paper claims to provide a rigorous quantitative framework for understanding the co-evolutionary dynamics of lung cancer, drug resistance, and immune escape. Key contributions include:

Mechanistic Insight: The model elucidates how M2 macrophage polarization creates a protective sanctuary for resistant tumor sublineages, highlighting the necessity of multi-target strategies that combine chemotherapy with therapies to repolarize M2 macrophages to M1.
Therapeutic Optimization: By integrating optimal control theory, the study offers a mathematical basis for designing adaptive drug dosing protocols that minimize the selection of resistant strains while managing systemic toxicity.
Predictive Capability: The derivation of $R_0$ and stability analysis provides a threshold for evaluating whether current treatment strategies are sufficient to control tumor growth or if they risk disease resurgence.
Methodological Rigor: The study emphasizes the importance of model selection, demonstrating that reduced models can be statistically superior when full complexity does not yield proportional gains in predictive accuracy.

The authors conclude that while the model relies on cross-sectional data and steady-state assumptions due to limited longitudinal data, it establishes a flexible foundation for future translational research. The framework aims to guide the development of personalized therapeutic strategies that address the complex interplay between tumor evolution, the immune microenvironment, and drug resistance.

More like this